Both companies may succeed in this industry.

Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on ...

This biotech has candidates in late-stage clinical development.

Eli Lilly looks undervalued as earnings forecasts rise and GLP-1 catalysts near. Read the full analysis here of LLY stock.

Although the stock is trading at a premium valuation, the company’s outstanding operational performance, strong financial ...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

The company got some bad news to start 2026.

This drugmaker continues to strengthen its investment thesis.

Microsoft beat software peers as Azure's 25% cloud share and OpenAI-led AI lift cash flow, despite competition, regulation and rising AI capex.

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The company still has a robust business that is delivering excellent results and ...

Both companies now aim to win in the oral weight loss drug market.